Summary
9.13 0.26(2.91%)07/03/2024
ICU (ICU)
ICU (ICU)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.91 | -4.20 | 1.98 | -15.95 | -7.56 | -91.38 | 0.00 | -91.48 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 9.13 | |
| Open | 9.23 | |
| High | 9.89 | |
| Low | 8.63 | |
| Volume | 288,470 | |
| Change | 0.26 | |
| Change % | 2.91 | |
| Avg Volume (20 Days) | 2,422,594 | |
| Volume/Avg Volume (20 Days) Ratio | 0.12 | |
| 52 Week Range | 0.16 - 6.23 | |
| Price vs 52 Week High | 46.52% | |
| Price vs 52 Week Low | 5,605.19% | |
| Range | -6.84 | |
| Gap Up/Down | -0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 28 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 0.00 | |
| Book Value | 0.0000 | |
| Earnings Per Share | 0.0000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | 0.0000 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 0 | |
| Shares Float | 0 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 0.00 | |
07/03 08:30 EST - globenewswire.com
SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device
DENVER, July 03, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has agreed to the final labeling for SeaStar Medical's QUELIMMUNE™, the Selective Cytopheretic Device for pediatric patients, paving the way under the Humanitarian Use Device (HUD) designation to market the therapeutic device in the U.S. for the treatment of children weighing 10 kilograms or more with acute kidney injury (AKI) and sepsis or septic condition requiring kidney replacement therapy (KRT).
SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device
DENVER, July 03, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has agreed to the final labeling for SeaStar Medical's QUELIMMUNE™, the Selective Cytopheretic Device for pediatric patients, paving the way under the Humanitarian Use Device (HUD) designation to market the therapeutic device in the U.S. for the treatment of children weighing 10 kilograms or more with acute kidney injury (AKI) and sepsis or septic condition requiring kidney replacement therapy (KRT).
06/11 08:30 EST - globenewswire.com
SeaStar Medical's Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology
DENVER, June 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that its patented, cell-directed, extracorporeal Selective Cytopheretic Device (SCD) is being featured in two presentations at the 42 nd Vicenza Course AKI-CRRT-ECOS and Critical Care Nephrology conference today, June 11, 2024. The International Vicenza Course – a scientific program that integrates industry-sponsored symposia, meet-the-expert sessions and short presentations – is being held June 11-13 in Vicenza, Italy.
SeaStar Medical's Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology
DENVER, June 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that its patented, cell-directed, extracorporeal Selective Cytopheretic Device (SCD) is being featured in two presentations at the 42 nd Vicenza Course AKI-CRRT-ECOS and Critical Care Nephrology conference today, June 11, 2024. The International Vicenza Course – a scientific program that integrates industry-sponsored symposia, meet-the-expert sessions and short presentations – is being held June 11-13 in Vicenza, Italy.
06/10 08:30 EST - globenewswire.com
SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company
DENVER, June 10, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) announces that three new members have joined its Board of Directors. Two new directors, Jennifer A. Baird and Bernadette N. Vincent, were elected at the Company's 2024 Annual Meeting of Stockholders held on June 4, and John Neuman was appointed to the Board on June 5. Former directors Bruce Rodgers and Richard Russell did not stand for reelection at the 2024 Annual Meeting, and Andres Lobo announced his retirement from Dow Chemical, resulting in his departure from the SeaStar Medical Board.
SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company
DENVER, June 10, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) announces that three new members have joined its Board of Directors. Two new directors, Jennifer A. Baird and Bernadette N. Vincent, were elected at the Company's 2024 Annual Meeting of Stockholders held on June 4, and John Neuman was appointed to the Board on June 5. Former directors Bruce Rodgers and Richard Russell did not stand for reelection at the 2024 Annual Meeting, and Andres Lobo announced his retirement from Dow Chemical, resulting in his departure from the SeaStar Medical Board.
06/07 08:30 EST - globenewswire.com
Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical's Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation
DENVER, June 07, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the publication of a peer-reviewed article in Nature Scientific Reports that describes the mechanism of action of the Company's Selective Cytopheretic Device (SCD) in the immunomodulation of excessive inflammation. “ Immunomodulatory effects of a cell progressing device to ameliorate dysregulated hyperinflammatory disease states ,” authored by Angela J. Westover, H. David Humes and Christopher J. Pino, (2024) 14:12747, investigated the SCD as an evolving approach to treating organ dysfunction arising from hyperinflammation and the cytokine storm by processing leukocytes in an extracorporeal circuit.
Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical's Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation
DENVER, June 07, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the publication of a peer-reviewed article in Nature Scientific Reports that describes the mechanism of action of the Company's Selective Cytopheretic Device (SCD) in the immunomodulation of excessive inflammation. “ Immunomodulatory effects of a cell progressing device to ameliorate dysregulated hyperinflammatory disease states ,” authored by Angela J. Westover, H. David Humes and Christopher J. Pino, (2024) 14:12747, investigated the SCD as an evolving approach to treating organ dysfunction arising from hyperinflammation and the cytokine storm by processing leukocytes in an extracorporeal circuit.
06/06 16:05 EST - globenewswire.com
SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Eric Schlorff, CEO, will hold a fireside chat at the Virtual Emerging Growth Conference on Wednesday, June 12 at 12:35 p.m. Eastern time (9:35 a.m. Pacific time).
SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Eric Schlorff, CEO, will hold a fireside chat at the Virtual Emerging Growth Conference on Wednesday, June 12 at 12:35 p.m. Eastern time (9:35 a.m. Pacific time).
06/06 08:30 EST - globenewswire.com
SeaStar Medical Announces 25-for-1 Reverse Stock Split
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the Company's 25-for-1 reverse stock split, which will become effective at June 7, 2024 at 5:00 PM EDT. The Company's common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market (Nasdaq) effective with the open of the market on June 10, 2024. SeaStar Medical's stock will continue to trade under the ticker symbol “ICU.”
SeaStar Medical Announces 25-for-1 Reverse Stock Split
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the Company's 25-for-1 reverse stock split, which will become effective at June 7, 2024 at 5:00 PM EDT. The Company's common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market (Nasdaq) effective with the open of the market on June 10, 2024. SeaStar Medical's stock will continue to trade under the ticker symbol “ICU.”
05/22 08:30 EST - globenewswire.com
Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical's Selective Cytopheretic Device Who Achieved Transplant Eligibility
SCD's ability to improve clinical status of four critically ill pediatric and adult patients across multiple clinical conditions published in Transplantation Direct
Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical's Selective Cytopheretic Device Who Achieved Transplant Eligibility
SCD's ability to improve clinical status of four critically ill pediatric and adult patients across multiple clinical conditions published in Transplantation Direct
05/20 04:42 EST - https://www.defenseworld.net
Swiss National Bank Lowers Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)
Swiss National Bank decreased its holdings in ICU Medical, Inc. (NASDAQ:ICUI – Free Report) by 10.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,419 shares of the medical instruments supplier’s stock after selling 4,600 shares during the quarter. Swiss National Bank owned about 0.17% of ICU Medical worth $4,031,000 at the end of the most recent quarter. A number of other large investors have also recently bought and sold shares of ICUI. WCM Investment Management LLC boosted its stake in shares of ICU Medical by 37.5% during the fourth quarter. WCM Investment Management LLC now owns 242,808 shares of the medical instruments supplier’s stock worth $24,223,000 after buying an additional 66,221 shares during the period. State of Alaska Department of Revenue grew its stake in shares of ICU Medical by 417.8% in the 4th quarter. State of Alaska Department of Revenue now owns 12,475 shares of the medical instruments supplier’s stock valued at $1,244,000 after purchasing an additional 10,066 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of ICU Medical by 7.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 168,957 shares of the medical instruments supplier’s stock valued at $20,108,000 after purchasing an additional 11,364 shares during the period. Louisiana State Employees Retirement System acquired a new position in shares of ICU Medical in the fourth quarter valued at approximately $1,007,000. Finally, Federated Hermes Inc. raised its stake in shares of ICU Medical by 6.5% during the third quarter. Federated Hermes Inc. now owns 125,967 shares of the medical instruments supplier’s stock worth $14,991,000 after purchasing an additional 7,675 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock. Wall Street Analyst Weigh In Separately, KeyCorp boosted their price objective on shares of ICU Medical from $134.00 to $136.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. Check Out Our Latest Report on ICU Medical Insider Activity at ICU Medical In other ICU Medical news, Director Elisha W. Finney sold 300 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $104.95, for a total transaction of $31,485.00. Following the transaction, the director now directly owns 2,129 shares in the company, valued at $223,438.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other ICU Medical news, COO Christian B. Voigtlander sold 13,603 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $107.19, for a total transaction of $1,458,105.57. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Elisha W. Finney sold 300 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $104.95, for a total value of $31,485.00. Following the completion of the transaction, the director now owns 2,129 shares of the company’s stock, valued at approximately $223,438.55. The disclosure for this sale can be found here. Insiders sold 26,562 shares of company stock worth $2,788,117 over the last 90 days. Company insiders own 6.70% of the company’s stock. ICU Medical Stock Performance NASDAQ ICUI opened at $103.99 on Monday. The stock has a market capitalization of $2.53 billion, a price-to-earnings ratio of -42.44 and a beta of 0.72. The business’s 50 day moving average is $100.63 and its two-hundred day moving average is $97.29. ICU Medical, Inc. has a 12-month low of $78.28 and a 12-month high of $196.57. The company has a current ratio of 2.61, a quick ratio of 1.09 and a debt-to-equity ratio of 0.76. ICU Medical (NASDAQ:ICUI – Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.39. ICU Medical had a positive return on equity of 5.38% and a negative net margin of 2.63%. The firm had revenue of $587.86 million for the quarter, compared to analyst estimates of $564.77 million. Research analysts expect that ICU Medical, Inc. will post 3.53 EPS for the current year. ICU Medical Company Profile (Free Report) ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Swiss National Bank Lowers Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)
Swiss National Bank decreased its holdings in ICU Medical, Inc. (NASDAQ:ICUI – Free Report) by 10.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,419 shares of the medical instruments supplier’s stock after selling 4,600 shares during the quarter. Swiss National Bank owned about 0.17% of ICU Medical worth $4,031,000 at the end of the most recent quarter. A number of other large investors have also recently bought and sold shares of ICUI. WCM Investment Management LLC boosted its stake in shares of ICU Medical by 37.5% during the fourth quarter. WCM Investment Management LLC now owns 242,808 shares of the medical instruments supplier’s stock worth $24,223,000 after buying an additional 66,221 shares during the period. State of Alaska Department of Revenue grew its stake in shares of ICU Medical by 417.8% in the 4th quarter. State of Alaska Department of Revenue now owns 12,475 shares of the medical instruments supplier’s stock valued at $1,244,000 after purchasing an additional 10,066 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of ICU Medical by 7.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 168,957 shares of the medical instruments supplier’s stock valued at $20,108,000 after purchasing an additional 11,364 shares during the period. Louisiana State Employees Retirement System acquired a new position in shares of ICU Medical in the fourth quarter valued at approximately $1,007,000. Finally, Federated Hermes Inc. raised its stake in shares of ICU Medical by 6.5% during the third quarter. Federated Hermes Inc. now owns 125,967 shares of the medical instruments supplier’s stock worth $14,991,000 after purchasing an additional 7,675 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock. Wall Street Analyst Weigh In Separately, KeyCorp boosted their price objective on shares of ICU Medical from $134.00 to $136.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. Check Out Our Latest Report on ICU Medical Insider Activity at ICU Medical In other ICU Medical news, Director Elisha W. Finney sold 300 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $104.95, for a total transaction of $31,485.00. Following the transaction, the director now directly owns 2,129 shares in the company, valued at $223,438.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other ICU Medical news, COO Christian B. Voigtlander sold 13,603 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $107.19, for a total transaction of $1,458,105.57. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Elisha W. Finney sold 300 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $104.95, for a total value of $31,485.00. Following the completion of the transaction, the director now owns 2,129 shares of the company’s stock, valued at approximately $223,438.55. The disclosure for this sale can be found here. Insiders sold 26,562 shares of company stock worth $2,788,117 over the last 90 days. Company insiders own 6.70% of the company’s stock. ICU Medical Stock Performance NASDAQ ICUI opened at $103.99 on Monday. The stock has a market capitalization of $2.53 billion, a price-to-earnings ratio of -42.44 and a beta of 0.72. The business’s 50 day moving average is $100.63 and its two-hundred day moving average is $97.29. ICU Medical, Inc. has a 12-month low of $78.28 and a 12-month high of $196.57. The company has a current ratio of 2.61, a quick ratio of 1.09 and a debt-to-equity ratio of 0.76. ICU Medical (NASDAQ:ICUI – Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.39. ICU Medical had a positive return on equity of 5.38% and a negative net margin of 2.63%. The firm had revenue of $587.86 million for the quarter, compared to analyst estimates of $564.77 million. Research analysts expect that ICU Medical, Inc. will post 3.53 EPS for the current year. ICU Medical Company Profile (Free Report) ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
05/16 08:30 EST - accesswire.com
1847 Reports 15.0% Increase in Revenue to $14.9 Million for the First Quarter of 2024
Gross profit increases 13.3% in Q1 2024 vs Q1 2023 NEW YORK, NY / ACCESSWIRE / May 16, 2024 / 1847 Holdings LLC("1847" or the "Company") (NYSE American:EFSH), a holding company specializing in identifying over-looked, deep value investment opportunities in middle market businesses, today provided a business update and reported financial results for the first quarter ended March 31, 2024. Q1 2024 Key Highlights Total Revenue was $14.9M in Q1 2024 compared to $13.0M in Q1 2023, a 15.0% year-over-year increase Gross profit was $5.6M in Q1 2024 compared to $4.9M in Q1 2023, a 13.3% year-over-year increase Executed Letter of Intent to Sell 1847 Cabinets Inc. for $27.6 Million Executed non-binding LOI to acquire a large, established millwork, cabinetry and door manufacturer based in Las Vegas, NV with revenues of $28.6 million, with a purchase price of $16.75 million which represents approximately 3.2x 2023 EBITDA Announced ICU Eyewear subsidiary diversified manufacturing to reduce production costs and fortify supply chain Announced ICU Eyewear subsidiary's strategic expansion of partnerships, adding 300 new locations with leading US retailer Completed refinancing and upsizing of $15 million revolving credit facility for ICU Eyewear subsidiary Expanded Wolo Manufacturing Corp subsidiary into India through supply chain diversification program Restructured promissory notes to non-dilutive debt instruments Divested Asien's Appliance business, significantly enhancing balance sheet Mr.
1847 Reports 15.0% Increase in Revenue to $14.9 Million for the First Quarter of 2024
Gross profit increases 13.3% in Q1 2024 vs Q1 2023 NEW YORK, NY / ACCESSWIRE / May 16, 2024 / 1847 Holdings LLC("1847" or the "Company") (NYSE American:EFSH), a holding company specializing in identifying over-looked, deep value investment opportunities in middle market businesses, today provided a business update and reported financial results for the first quarter ended March 31, 2024. Q1 2024 Key Highlights Total Revenue was $14.9M in Q1 2024 compared to $13.0M in Q1 2023, a 15.0% year-over-year increase Gross profit was $5.6M in Q1 2024 compared to $4.9M in Q1 2023, a 13.3% year-over-year increase Executed Letter of Intent to Sell 1847 Cabinets Inc. for $27.6 Million Executed non-binding LOI to acquire a large, established millwork, cabinetry and door manufacturer based in Las Vegas, NV with revenues of $28.6 million, with a purchase price of $16.75 million which represents approximately 3.2x 2023 EBITDA Announced ICU Eyewear subsidiary diversified manufacturing to reduce production costs and fortify supply chain Announced ICU Eyewear subsidiary's strategic expansion of partnerships, adding 300 new locations with leading US retailer Completed refinancing and upsizing of $15 million revolving credit facility for ICU Eyewear subsidiary Expanded Wolo Manufacturing Corp subsidiary into India through supply chain diversification program Restructured promissory notes to non-dilutive debt instruments Divested Asien's Appliance business, significantly enhancing balance sheet Mr.
04/30 08:30 EST - globenewswire.com
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure
DENVER, April 30, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the National Institutes of Health's (NIH) National Heart, Lung, and Blood Institute has awarded a $3.6 million grant for a clinical trial to evaluate the Selective Cytopheretic Device Adult (SCD-ADULT, a member of the Company's Quelimmune™ product family) as a bridging strategy to left ventricular assist device (LVAD) implantation in patients with chronic heart failure (CHF) who have progressed to acute decompensated heart failure (ADHF). This grant award follows a Breakthrough Device Designation for cardiorenal syndrome granted by the U.S. Food and Drug Administration (FDA's) Center for Biologics Evaluation and Research (CBER) in September 2023.
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure
DENVER, April 30, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the National Institutes of Health's (NIH) National Heart, Lung, and Blood Institute has awarded a $3.6 million grant for a clinical trial to evaluate the Selective Cytopheretic Device Adult (SCD-ADULT, a member of the Company's Quelimmune™ product family) as a bridging strategy to left ventricular assist device (LVAD) implantation in patients with chronic heart failure (CHF) who have progressed to acute decompensated heart failure (ADHF). This grant award follows a Breakthrough Device Designation for cardiorenal syndrome granted by the U.S. Food and Drug Administration (FDA's) Center for Biologics Evaluation and Research (CBER) in September 2023.
04/28 09:45 EST - prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU
NEW YORK , April 28, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SeaStar Medical Holding Corporation ("SeaStar" or the "Company") (NASDAQ: ICU). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU
NEW YORK , April 28, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SeaStar Medical Holding Corporation ("SeaStar" or the "Company") (NASDAQ: ICU). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
04/17 16:00 EST - globenewswire.com
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update.
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update.
04/11 08:30 EST - globenewswire.com
SeaStar Medical to Present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference
DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18 at 9:30 a.m. Eastern time. The formal presentation will be followed by a hosted question-and-answer session.
SeaStar Medical to Present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference
DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18 at 9:30 a.m. Eastern time. The formal presentation will be followed by a hosted question-and-answer session.
03/27 08:30 EST - globenewswire.com
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that it will restate its financial statements for the fiscal year ended December 31, 2022 and for the interim periods ended March 31, 2023, June 30, 2023 and September 30, 2023. The restatement will impact the accounting treatment and classification of certain outstanding warrants and the prepaid forward purchase arrangement that was terminated in June 2023.
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that it will restate its financial statements for the fiscal year ended December 31, 2022 and for the interim periods ended March 31, 2023, June 30, 2023 and September 30, 2023. The restatement will impact the accounting treatment and classification of certain outstanding warrants and the prepaid forward purchase arrangement that was terminated in June 2023.
03/22 02:15 EST - watchdoguganda.com
Mulago Hospital seeks Shs10 billion for ICUs
Mulago National Referral Hospital is in need of over Shs10 billion to fully functionalise its intensive care units (ICU). This request was tabled by the hospital’s Ag. Executive Director, Dr. Rosemary Byanyima while appearing before the Committee on Health on Thursday, 21 March 2024. According to Dr. Byanyima, Shs 122billion allocated to Mulago is inadequate […] The post Mulago Hospital seeks Shs10 billion for ICUs appeared first on Watchdog Uganda...
Mulago Hospital seeks Shs10 billion for ICUs
Mulago National Referral Hospital is in need of over Shs10 billion to fully functionalise its intensive care units (ICU). This request was tabled by the hospital’s Ag. Executive Director, Dr. Rosemary Byanyima while appearing before the Committee on Health on Thursday, 21 March 2024. According to Dr. Byanyima, Shs 122billion allocated to Mulago is inadequate […] The post Mulago Hospital seeks Shs10 billion for ICUs appeared first on Watchdog Uganda...
03/12 08:30 EST - globenewswire.com
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients
Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides updates on the acute kidney injury (AKI) programs it is developing with its patented, first-to-market, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill patients with AKI. “We now have 21 subjects enrolled across five clinical sites in our NEUTRALIZE-AKI pivotal clinical trial, which is intended to evaluate the safety and efficacy of our SCD in adult AKI patients.
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients
Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides updates on the acute kidney injury (AKI) programs it is developing with its patented, first-to-market, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill patients with AKI. “We now have 21 subjects enrolled across five clinical sites in our NEUTRALIZE-AKI pivotal clinical trial, which is intended to evaluate the safety and efficacy of our SCD in adult AKI patients.